Intertek is the industry leader with over 43,000 people in 1,000 locations in over 100 countries. Whether your business is local or global, we can ensure your products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world.
Ligand binding assay (LBA) development and validation for PK, TK, PD and immunogenicity assessment supporting biologic preclinical and clinical development
Ligand-binding assays (LBA) is the industry accepted method for quantification of proteins, antibodies, DNA, ribonucleic acids, biosimilars and other large molecules in pharmacokinetic (PK), toxicokinetic (TK), pharmcodynamic (PD) and immunogenicity studies during preclinical and clinical development.
Ligand-binding assays are challenging due to specific and non-specific interfering matrix components and as a result, establishing method selectivity, specificity and range of quantitation can be difficult to achieve. Sample matrix interferences, can lead to unreliable PK data, and occur due to the presence of interfering substances such as lipids, serum proteins, anticoagulants, binding proteins or other factors such as ionic strength, pH or viscosity.
Each ligand binding assay must be developed using the most appropriate assay format and must be validated to ensure robust and reliable data to support critical decision making. Strategic approaches to method development ensure optimization of the assay’s selectivity, specificity, and quantitation range whilst minimizing matrix interference effects. Our team ensures that the validated assay meets worldwide regulatory requirements.
Our ligand binding assay experts are experienced in selection of the most suitable assay format, including enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence assays (ECL) or radioimmunoassay (RIA), cell-free and cell-based assay formats.
We understand the importance of well characterized ligand binding assay reagents as variation in reagent specificity and binding affinity can lead to differences in assay performance. Whilst some LBA reagents are commercially available others may need to be specifically produced. Through our biologics characterisation laboratories, we can fully characterize these biomolecule reagents and monitor for quality and batch-to-batch and lot-to-lot differences.
By selecting Intertek, you gain an bioanalysis services outsourcing partner with extensive experience in ligand binding assay method development, validation and bioanalytical support for PK assessment and data submission. We anticipate all sources of risks related to the use of a validated ligand binding assay so that you will obtain the highest quality, regulatory-driven data you need during preclinical and clinical development.